Nektar Therapeutics NKTR Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $5.7M+78.3% | $3.2M-71.8% | $11.35M+79.2% | $6.33M-11.1% | $7.12M-27.5% | ||
| $419.03M+81.7% | $230.64M+0.6% | $229.18M+72.4% | $132.92M-26.1% | $179.74M-14.8% | ||
| $589.04M+121% | $266.27M-5.4% | $281.36M+50.8% | $186.57M-18.9% | $229.91M-12.0% | ||
| $763.27M+172% | $280.41M-6.9% | $301.35M+45.2% | $207.53M-19.0% | $256.24M-15.7% | ||
| $10.03M-6.9% | $10.77M-30.8% | $15.56M+9.0% | $14.28M-19.9% | $17.83M+54.3% | ||
| $57.71M+7.8% | $53.54M-19.3% | $66.34M-7.1% | $71.39M+0.6% | $70.93M+15.5% | ||
| $187.06M-1.8% | $190.57M-11.9% | $216.26M-6.7% | $231.75M-4.4% | $242.5M-0.3% | ||
| 390M0.0% | 390M0.0% | 390M+30.0% | 300M0.0% | 300M+29,999,900% | ||
| -$3.81B-1.2% | -$3.76B-1.0% | -$3.72B-1.0% | -$3.69B-1.1% | -$3.65B-1.4% | ||
| $576.22M+541% | $89.83M+5.6% | $85.09M+451% | -$24.21M-276% | $13.74M-77.4% | ||
| $763.27M+172% | $280.41M-6.9% | $301.35M+45.2% | $207.53M-19.0% | $256.24M-15.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Nektar Therapeutics cover its short-term obligations?
- Its current ratio is 10.21 — current assets exceed current liabilities.
- Where does Nektar Therapeutics's balance sheet data come from?
- Every line is extracted from Nektar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.